 SAN DIEGO , Sept. 15, 2022 PRNewswire -- Neurocrine Biosciences, Inc. NASDAQ: NBIX today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia TD symptoms while maintaining control of the underlying psychiatric disorder. 